Trauma Triage and Trauma System Performance

par Johnson, Gary
Publié dans West J Emerg Med (2016)

Management of Sickle Cell Disease Super Utilizers

par Johnson, Gary A.
Publié dans West J Emerg Med (2017)

Noncanonical Function of MEKK2 and MEK5 PB1 Domains for Coordinated Extracellular Signal-Regulated Kinase 5 and c-Jun N-Terminal Kinase Signaling

par Nakamura, Kazuhiro, Johnson, Gary L.
Publié 2007

The c-Jun Kinase/Stress-activated Pathway: Regulation, Function and Role in Human Disease

par Johnson, Gary L., Nakamura, Kazuhiro
Publié 2007

Sequence patches on MAPK surfaces define protein-protein interactions

par Johnson, Gary L, Gomez, Shawn M
Publié 2009

Implications of Mesenchymal Cells in Cancer Stem Cell Populations: Relevance to EMT

par Abell, Amy N., Johnson, Gary L.
Publié dans Curr Pathobiol Rep (2014)

MEK Inhibition in Non-Small Cell Lung Cancer

par Stinchcombe, Thomas E., Johnson, Gary L.
Publié dans Lung Cancer (2014)

Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-a...

par Knall, Cindy, Worthen, G. Scott, Johnson, Gary L.
Publié 1997

Data-driven modeling of cellular stimulation, signaling and output response in RAW 264.7 cells

par Wu, Yang, Johnson, Gary L, Gomez, Shawn M
Publié 2008

MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis

par Pham, Trang T., Angus, Steven P., Johnson, Gary L.
Publié 2013

Assessing adaptation of the cancer kinome in response to targeted therapies

par Zawistowski, Jon S., Graves, Lee M., Johnson, Gary L.
Publié dans Biochem Soc Trans (2014)

Identification of Ponatinib and Other Known Kinase Inhibitors with Potent MEKK2 Inhibitory Activity

par Ahmad, Syed, Johnson, Gary L., Scott, John E.
Publié dans Biochem Biophys Res Commun (2015)

Landscaping a chromatin response to MEK inhibition

par Zawistowski, Jon S., Goulet, Daniel R., Johnson, Gary L.
Publié dans Cell Cycle (2017)

Pharmacologic targeting of drug-induced enhancers

par Zawistowski, Jon S., Bevill, Samantha M., Johnson, Gary L.
Publié dans Oncoscience (2017)

Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer

par Bevill, Samantha M., Zawistowski, Jon S., Johnson, Gary L.
Publié dans Mol Cell Oncol (2017)

Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer

par Jordan, Nicole Vincent, Johnson, Gary L, Abell, Amy N
Publié 2011

Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains

par Stuhlmiller, Timothy J., Miller, Samantha M., Johnson, Gary L.
Publié dans Mol Cell Oncol (2015)

Identification of the glucagon receptor in rat liver membranes by photoaffinity crosslinking

par Johnson, Gary L., MacAndrew, Vincent I., Pilch, Paul F.
Publié 1981

Phenotypic Characterization of a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis

par Katz, Martin L., Johnson, Gary S., Tullis, Gregory E., Lei, Bo
Publié 2007

Fluorochrome-Labeled Inhibitors of Caspases: Convenient In Vitro and In Vivo Markers of Apoptotic Cells for Cytometric Analysis

par Darzynkiewicz, Zbigniew, Pozarowski, Piotr, Lee, Brian W., Johnson, Gary L.
Publié 2011